Short-term prognosis of breakthrough venous thromboembolism in anticoagulated patients
Open Access
- 1 March 2020
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 187, 125-130
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN StudyJournal of Thrombosis and Haemostasis, 2015
- Parenteral anticoagulation in ambulatory patients with cancer2014
- Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trialsBlood, 2014
- Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosisThrombosis Research, 2014
- Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patientsJournal of Thrombosis and Haemostasis, 2009
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005
- Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with CancerNew England Journal of Medicine, 2003
- Venous Thromboembolism and Cancer: Risks and OutcomesCirculation, 2003
- Risk Factors for Deep Vein Thrombosis and Pulmonary EmbolismArchives of internal medicine (1960), 2000
- ANTICOAGULANT DRUGS IN THE TREATMENT OF PULMONARY EMBOLISMThe Lancet, 1960